LifeNet Health features best-in-class orthobiologic solutions at AAOS Annual Meeting
LifeNet Health features best-in-class orthobiologic solutions at AAOS Annual Meeting
SAN DIEGO, Aug. 31, 2021 /PRNewswire/ -- LifeNet Health, the world's leading provider of allograft biologics, is showcasing its comprehensive portfolio of advanced biomaterials at the 2021 AAOS Annual Meeting (Booth #1527) Sept. 1-3.
圣迭戈，2021年8月31日/美通社/--世界领先的同种异体移植生物制品供应商LifeNet Health将在2021年AAOS年会(展位#1527)上展示其先进生物材料的全面产品组合。1比3。
Its featured solutions include ViviGen® Cellular Bone Matrix, the first and only osteobiologic designed to recover and maintain lineage-committed bone cells; ArthroFlex® SCR acellular dermal matrix, the gold standard for superior capsular reconstruction; and FlexiGraft® QuadLink™, the only pre-sutured quadriceps tendon for ACL reconstruction.
其特色解决方案包括VIviGen®细胞骨基质，这是第一个也是唯一一个旨在恢复和维持骨系细胞的骨生物学；ArthroFlex®SCR脱细胞真皮基质，高级包膜重建的黄金标准；以及Flexigraft®Quadlink™，唯一用于前交叉韧带重建的预先缝合的股四头肌腱。
"Our portfolio reflects close collaboration with clinicians to understand the challenges they face in helping their patients heal," said Daniel Osborne, LifeNet Health Vice President of Global Marketing and Commercial Strategy. "Combined with our unique technologies, this insight enables LifeNet Health to make better biologics that are uniquely engineered to address those challenges, and the data being shared at AAOS shows that's precisely what they do."
LifeNet Health负责全球营销和商业战略的副总裁丹尼尔·奥斯本(Daniel Osborne)说：“我们的产品组合反映了与临床医生的密切合作，以了解他们在帮助患者康复方面面临的挑战。与我们独特的技术结合在一起，这种洞察力使LifeNet Health能够制造出更好的生物制品，这些生物制品是为应对这些挑战而独特设计的，AAOS分享的数据表明，这正是他们所做的。“
Live Presentations — In-Person or Online
In addition to its exhibit hall and digital presence, LifeNet Health's AAOS activities include live programming to provide the latest clinical and economic data about its world-class biologics.
现场演示-面对面或在线
除了展厅和数字展示，LifeNet Health的AAOS活动还包括现场编程，以提供有关其世界级生物制剂的最新临床和经济数据。
Elena Gianulis, PhD, LifeNet Health's Medical Science Liaison, will lead two in-booth presentations on two of the most-advanced allograft bone-healing solutions available, ViviGen and PliaFX® Prime. The first session explores the growing body of evidence showing ViviGen supports healing in trauma, extremity and spine procedures, including recent studies that showed ViviGen supports outcomes equivalent to autograft1,2 and superior to mesenchymal stem cell (MSC)-based grafts in even high-risk foot and ankle procedures.
LifeNet Health医学科学联络人Elena Gianulis博士将主持两场关于ViviGen和Paria FX®Prime这两种最先进的同种异体骨愈合解决方案的展位演讲。第一部分探讨了越来越多的证据表明ViviGen支持创伤、四肢和脊柱手术的愈合，包括最近的研究表明ViviGen支持等同于自体移植的结果1,2甚至在高危足踝手术中也优于以间充质干细胞(MSC)为基础的移植物。
The second session will focus on how the unique technology of PliaFX Prime 100% bone moldable demineralized fibers supports effective clinical outcomes while providing exceptional value to hospitals. The presentations take place at 3:10 p.m. PDT Sept. 1 and Sept. 2 and will be streamed live to LifeNet Health's online showcase.
第二场会议将重点介绍Paria FX Prime 100%骨可模塑脱钙纤维的独特技术如何在为医院提供非凡价值的同时，支持有效的临床结果。演讲将于下午3点10分举行。PDT9月1.和9月1日。2，并将在LifeNet Health的在线展示中进行现场直播。
AAOS-Hosted Innovation Theater Sessions
Two surgeons will present at AAOS Innovation Theater sessions about their experience using ViviGen and the results it is providing for their patients.
AAOS主办的创新剧院会议
两名外科医生将在AAOS创新剧院会议上介绍他们使用ViviGen的经验以及它为他们的患者提供的结果。
Richard Yoon, MD, director of Orthopedic Research in the Division of Orthopedic Trauma and Adult Reconstruction at Jersey City Medical Center, will describe his use of ViviGen in a series of challenging trauma cases. He also will discuss the 500-patient trauma registry he is leading that will collect data at seven Level 1 trauma centers to describe both the safety and efficacy of ViviGen.
泽西市医疗中心整形外科创伤和成人重建部整形外科研究主任Richard Yoon医学博士将介绍他在一系列具有挑战性的创伤案例中使用ViviGen的情况。他还将讨论他领导的500名患者的创伤登记，该登记将在7个一级创伤中心收集数据，以描述ViviGen的安全性和有效性。
Joseph Park, MD, associate professor and chief of the Foot and Ankle Davison in the Department of Orthopaedic Surgery at UVA, will present findings from his 135-patient retrospective review of ViviGen in high-risk foot and ankle surgeries, showing that patients treated with ViviGen experienced outcomes equivalent to those reported in literature for autograft.
弗吉尼亚大学整形外科副教授兼足部和踝部主任、医学博士约瑟夫·帕克将发表他对ViviGen在高风险足部和踝部手术中135名患者的回顾性研究结果，结果显示，接受ViviGen治疗的患者经历的结果与文献中报道的自体移植相同。
Learn more about LifeNet Health's activities at AAOS, as well as its portfolio of solutions for sports medicine, trauma, extremity and spine procedures, at www.LifeNetHealth.org/AAOS2021.
欲了解更多有关LifeNet Health在AAOS的活动及其运动医学、创伤、四肢和脊柱手术解决方案组合的信息，请访问www.LifeNetHealth.org/AAOS2021。
About LifeNet Health
LifeNet Health helps save lives, restore health, and give hope to thousands each year. It is the world's most trusted provider of transplant solutions — from organ procurement to bio-implants and cellular therapies — and a leader in regenerative medicine, while always honoring the donors and healthcare professionals who enable healing. For more information about LifeNet Health, go to www.lifenethealth.org.
关于LifeNet Health LifeNet Health每年帮助拯救生命、恢复健康，并给成千上万人带来希望。它是世界上最值得信赖的移植解决方案提供商-从器官采购到生物植入和细胞疗法-也是再生医学领域的领先者，同时始终向能够治愈的捐赠者和医疗保健专业人员致敬。有关LifeNet Health的更多信息，请访问Www.lifenethealth.org.
1. Lareau, et al. Does autogenous bone graft work? A logistic regression analysis of data from 159 papers in the foot and ankle literature. Foot Ankle Surg. 2015;21(3):150-159.
2. Muller, et al. Substitutes of structural and non-structural autologous bone grafts in hindfoot arthrodesis and osteotomies: a systemic review. BMC Musculoskeletal Disorders. 2013;14:59.
1.Lareau等人。自体骨移植有效吗？足踝文献159篇数据的Logistic回归分析。足踝手术，2015；21(3)：150-159。
2.Muller等人。结构性和非结构性自体骨移植在后足关节融合术和截骨术中的替代物：一项系统综述。BMC肌肉骨骼疾病。2013年；14：59。
SOURCE LifeNet Health
来源：LifeNet Health
Related Links
相关链接
http://www.LifeNetHealth.org
Http://www.LifeNetHealth.org